Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

COMy Virtual 2020

Highlights

View all
1:59
Myeloma: BiTEs & CARs
Shaji Kumar • 12 May 2020
8:13
Proteasome inhibitors: key drugs in multiple myeloma
Maria Victoria-Mateos • 14 May 2020
9:25
MGUS diagnosis: a step-by-step approach
Graham Jackson • 16 May 2020
11:27
Jesús San Miguel: Is myeloma curable?
Jesús San Miguel • 13 May 2020

Myeloma in the COVID-19 era

View all
2:28
The impact of COVID-19 on clinical practice
Irene Ghobrial • 28 Apr 2020
5:09
Addressing the imbalances & disparities amid COVID-19
Kenneth Anderson • 4 May 2020
2:10
Myeloma & COVID-19: minimizing risk while maximising treatment
Shaji Kumar • 11 May 2020
2:56
Novel drugs for myeloma thromboprophylaxis
Heinz Ludwig • 13 May 2020

MRD Updates

View all
1:37
MRD in myeloma
Keith Stewart • 30 Apr 2020
1:46
MRD: the most relevant prognostic factor in myeloma
Bruno Paiva • 15 May 2020
6:33
MRD as a tool to discontinue therapy in MM?
Luciano Costa • 11 May 2020
5:06
Amyloidosis treatment & response determination
Shaji Kumar • 11 May 2020

Transplant Updates

View all
1:36
Bortezomib and dexamethasone after ASCT for high-risk MM
Elena Zamagni • 6 May 2020
5:52
Transplant for all eligible MM patients?
Arnon Nagler • 15 May 2020
5:18
Upfront treatment in transplant candidates
Jesús San Miguel • 12 May 2020
3:19
Updates on multiple myeloma management
Elena Zamagni • 6 May 2020
The content of VJHemOnc is intended for healthcare professionals